Department of Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA.
School of Medicine and Health Sciences, The George Washington University, Washington, DC, USA.
Drug Metab Rev. 2021 May;53(2):188-206. doi: 10.1080/03602532.2021.1923728. Epub 2021 May 25.
As lead optimization efforts have successfully reduced metabolic liabilities due to cytochrome P450 (CYP)-mediated metabolism, there has been an increase in the frequency of involvement of non-CYP enzymes in the metabolism of investigational compounds. Although there have been numerous notable advancements in the characterization of non-CYP enzymes with respect to their localization, reaction mechanisms, species differences and identification of typical substrates, accurate prediction of non-CYP-mediated clearance, with a particular emphasis with the difficulties in accounting for any extrahepatic contributions, remains a challenge. The current manuscript comprehensively summarizes the recent advancements in the prediction of drug metabolism and the to extrapolation of clearance for substrates of non-CYP drug metabolizing enzymes.
随着先导优化工作成功降低了细胞色素 P450(CYP)介导的代谢导致的代谢性负担,非 CYP 酶在研究化合物代谢中的参与频率有所增加。尽管在非 CYP 酶的特征描述方面取得了许多显著进展,包括其定位、反应机制、种属差异和典型底物的鉴定,但准确预测非 CYP 介导的清除率仍然是一个挑战,特别是难以考虑到任何肝外贡献的情况下。本文全面总结了药物代谢预测以及非 CYP 药物代谢酶底物清除率外推的最新进展。